Patrizia Casalini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11538864/publications.pdf

Version: 2024-02-01

40 papers	4,423 citations	201674 27 h-index	330143 37 g-index
40 all docs	40 docs citations	40 times ranked	7131 citing authors

#	Article	IF	Citations
1	Intratumor lactate levels reflect HER2â€positive breast cancer. Journal of Cellular Physiology, 2019, 234, 1768-1779.	4.1	31
2	Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. Scientific Reports, 2019, 9, 14288.	3.3	17
3	The PDGFRÎ²/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. BMC Cancer, 2018, 18, 586.	2.6	16
4	MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. Oncotarget, 2018, 9, 27920-27928.	1.8	14
5	Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Letters, 2017, 384, 94-100.	7.2	131
6	CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. Oncotarget, 2016, 7, 69649-69665.	1.8	29
7	miR-9 and miR-200 Regulate PDGFRÎ²-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 5562-5572.	0.9	74
8	Conversion to stemâ€cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. Molecular Oncology, 2016, 10, 253-271.	4.6	120
9	Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells. Journal of Cellular Physiology, 2015, 230, 2661-2670.	4.1	13
10	Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. OncoImmunology, 2014, 3, e28989.	4.6	34
11	Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma. Cancer Discovery, 2014, 4, 110-129.	9.4	100
12	PDGFRÎ² and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. Molecular Oncology, 2014, 8, 968-981.	4.6	37
13	FOXP3 expression in tumor cells and implications for cancer progression. Journal of Cellular Physiology, 2013, 228, 30-35.	4.1	87
14	Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress. PLoS ONE, 2013, 8, e56761.	2.5	41
15	microRNA: New Players in Metastatic Process. , 2013, , .		2
16	Oncosuppressive role of p53â€induced miRâ€205 in triple negative breast cancer. Molecular Oncology, 2012, 6, 458-472.	4.6	142
17	Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood, 2012, 120, 3007-3018.	1.4	350
18	Current and Future Developments in Cancer Therapy Research: miRNAs as New Promising Targets or Tools. , 2012, , 517-546.		2

#	Article	IF	Citations
19	SPARC Oppositely Regulates Inflammation and Fibrosis in Bleomycin-Induced Lung Damage. American Journal of Pathology, 2011, 179, 3000-3010.	3.8	62
20	Breast cancer and microRNAs: therapeutic impact. Breast, 2011, 20, S63-S70.	2.2	87
21	microRNA-205 Regulates HER3 in Human Breast Cancer. Cancer Research, 2009, 69, 2195-2200.	0.9	334
22	FOXP3 Expression and Overall Survival in Breast Cancer. Journal of Clinical Oncology, 2009, 27, 1746-1752.	1.6	271
23	MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. European Journal of Cancer, 2008, 44, 2753-2759.	2.8	138
24	Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact. Clinical Cancer Research, 2008, 14, 25-31.	7.0	20
25	Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction. Journal of Immunotherapy, 2007, 30, 684-693.	2.4	70
26	MicroRNA Signatures in Human Ovarian Cancer. Cancer Research, 2007, 67, 8699-8707.	0.9	1,356
27	Relationship between p53 and p27 expression following HER2 signaling. Breast, 2007, 16, 597-605.	2.2	16
28	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. European Journal of Cancer, 2006, 42, 1057-1061.	2.8	8
29	Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene, 2004, 23, 2153-2160.	5.9	45
30	Role of HER receptors family in development and differentiation. Journal of Cellular Physiology, 2004, 200, 343-350.	4.1	201
31	Expression of Concern: HER2 signaling enhances 5â€²UTRâ€mediated translation of câ€Myc mRNA. Journal of Cellular Physiology, 2004, 200, 82-88.	4.1	31
32	HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer. Journal of Clinical Oncology, 2003, 21, 458-462.	1.6	99
33	HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clinical Cancer Research, 2002, 8, 520-5.	7.0	58
34	Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Nodeâ€"Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables. Journal of Clinical Oncology, 2001, 19, 329-335.	1.6	147
35	Role of p53 in HER2-induced Proliferation or Apoptosis. Journal of Biological Chemistry, 2001, 276, 12449-12453.	3.4	44
36	Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Research and Treatment, 1999, 55, 167-175.	2.5	44

#	Article	IF	Citations
37	Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression. , 1997, 72, 631-636.		19
38	Differential sensitivity of CD30+neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies. British Journal of Haematology, 1995, 90, 572-577.	2.5	14
39	Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification. International Journal of Cancer, 1991, 47, 933-937.	5.1	99
40	Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: Analysis of cell binding and internalization. International Journal of Cancer, 1991, 48, 284-290.	5.1	20